A Phase 3 interventional study of Evolocumab and Placebo in Coronary Artery Disease (CAD), sponsored by Amgen. Completed at 33 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 302 studies in Coronary Artery Disease with a site in Italy — 48 open to participants now, 71 under way, 7 of them phase 3. Coronary Artery Disease · Italy.
Among the 302 studies in Coronary Artery Disease with a site in Italy, this one is the 115th largest by enrollment of the 189 interventional ones that give a count, is one of 14 that started in 2018, is one of 37 in phase 3, and was the 182nd registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →48 of the 302 studies in Coronary Artery Disease with a site in Italy are open now. Recruiting first, the newest first:
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
IRCCS San Raffaele · Sites in Italy
Ages 18+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy, Poland, Romania and 1 more country
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
302 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 41 · Phase 4 57
First in 2000; this study’s year is marked. 14 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 290 across the 189 interventional studies, 400 across the 113 observational. Of the 151 that completed or were terminated, 35 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 302 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 3 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
13 of the studies in Coronary Artery Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06410690Centro Cardiologico MonzinoTrustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS | 2026-11-30 |
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT06321757Fundación EPICPREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients | 2026-12-30 |
| NCT07817524Fondazione Policlinico Universitario Agostino Gemelli IRCCSClinical Outcome of Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention in Patients With Severe Left Ventricular Disfunction (CROWN) | 2026-12-31 |
| NCT07291609Azienda Ospedaliera "Sant'Andrea"Microplastics and Nanoplastics in Patients With Chronic Coronary Syndromes | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 302 studies in Coronary Artery Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.
This study seeks to identify morphologic changes, such as increase in FCT in atherosclerotic plaques associated with treatment with evolocumab and maximally tolerated statin therapy with or without additional lipid-modifying medication in patients presenting with NSTE-ACS using optical coherence tomography (OCT; primary, secondary, and exploratory endpoints).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
No statin use: greater than or equal to 130 mg/dL Low- or moderate-intensity statin use greater than or equal to 80 mg/dL High-intensity statin use greater than or equal to 60 mg/dL
Angiographic evidence of coronary artery disease (CAD) with greater than or equal to 20% reduction of lumen diameter by angiographic visual estimation, in addition to the culprit plaque.
Left main coronary artery must not have a greater than 50% reduction in lumen diameter by visual angiographic estimation.
Targeted vessel:
May not be the culprit vessel for the current or a previous myocardial infarction (MI).
Has not undergone prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), and may not be a bypass graft.
May not be a candidate for PCI or CABG currently or over the next 12 months, in the opinion of the investigator.
Must be accessible by the optical coherence tomography (OCT) catheter.
Targeted segment:
Must have up to 50% but not greater than 50% reduction in lumen diameter by visual angiographic estimation and must be at least 40 mm in length.
Must contain at least 1 image with a fibrous cap thickness (FCT) of less than or equal to 120 μm and at least 1 image with a lipid arc of greater than 90° as determined by the imaging core laboratory Distal plaques of up to 50% stenosis by visual angiographic estimation are permitted, provided that such stenosis is not a target for PCI or CABG.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
Drug: Evolocumab · Drug: Statin therapy
Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
Drug: Placebo · Drug: Statin therapy
Participants will receive evolocumab (AMG 145) subcutaneous monthly.
Also known as: Repatha, AMG 145, EvoMab
Participants will receive matching placebo subcutaneous monthly.
high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.
Absolute Change From Baseline in Minimum FCT
Absolute change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
Time frame: Baseline, week 50
Percent Change From Baseline in Minimum FCT
Percent change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
Time frame: Baseline, week 50
Absolute Change From Baseline in Mean Minimum FCT
Absolute change from baseline in mean minimum FCT for all images assessed in an individual participant as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
Time frame: Baseline, week 50
Absolute Change From Baseline in the Maximum Lipid Arc
Absolute change from baseline in the maximum lipid arc in a matched segment of artery as determined by OCT. Lower value of lipid arc indicates a better situation.
Time frame: Baseline, week 50
Absolute Change From Baseline in Minimum FCT in Lipid Rich Plaques
Absolute change from baseline in minimum FCT in lipid rich plaques as determined by OCT. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Higher value of FCT indicates a better situation
Time frame: Baseline, week 50
Absolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques
Absolute change from baseline in maximum lipid arc in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid arc indicates a better situation.
Time frame: Baseline, week 50
Absolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques
Absolute change from baseline in lipid core length in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid core length indicates a better situation.
Time frame: Baseline, week 50
Participants were enrolled at 23 research centers in Australia (2), Czech Republic (2), Germany (2), Hungary (4), Italy (6), and the Netherlands (7), from November 2018 to December 2019.
| Milestone | Placebo | Evolocumab |
|---|---|---|
| Started | 82 | 82 |
| Received at least 1 dose of study drug | 81 | 80 |
| Completed | 76 | 79 |
| Not completed | 6 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 2 |
Absolute change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
| µm | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in Minimum FCT | 21.5 ± 5.2 | 42.7 ± 5.1 |
Percent change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
| percent change | Placebo | Evolocumab |
|---|---|---|
| Percent Change From Baseline in Minimum FCT | 44.30 ± 11.76 | 81.76 ± 10.94 |
Absolute change from baseline in mean minimum FCT for all images assessed in an individual participant as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.
| µm | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in Mean Minimum FCT | 29.78 ± 6.88 | 62.29 ± 5.95 |
Absolute change from baseline in the maximum lipid arc in a matched segment of artery as determined by OCT. Lower value of lipid arc indicates a better situation.
| degrees | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in the Maximum Lipid Arc | -31.4 ± 9.0 | -57.5 ± 7.4 |
Absolute change from baseline in minimum FCT in lipid rich plaques as determined by OCT. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Higher value of FCT indicates a better situation
| μm | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in Minimum FCT in Lipid Rich Plaques | 24.6 ± 5.5 | 40.6 ± 5.5 |
Absolute change from baseline in maximum lipid arc in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid arc indicates a better situation.
| degrees | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques | -31.9 ± 8.1 | -61.9 ± 7.9 |
Absolute change from baseline in lipid core length in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid core length indicates a better situation.
| mm | Placebo | Evolocumab |
|---|---|---|
| Absolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques | -3.33 ± 0.64 | -5.76 ± 0.61 |
Collected over All cause mortality reporting period is from the 1st dose of investigational product (IP) up to the end of study (EOS) date (Week 52). Adverse event (AE) reporting period is from the 1st dose of IP up to and including 30 days after the last dose of IP date or the EOS date (Week 52) whichever is earlier.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 2/82 (2.4%) | 16/81 (19.8%) | 30/81 (37%) |
| Evolocumab | 0/82 (0%) | 13/80 (16.3%) | 31/80 (38.8%) |
| Event | Placebo | Evolocumab |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 3/81 | 0/80 |
| Normocytic anaemiaBlood and lymphatic system disorders | 0/81 | 1/80 |
| Acute coronary syndromeCardiac disorders | 1/81 | 1/80 |
| Angina pectorisCardiac disorders | 0/81 | 1/80 |
| Coronary artery diseaseCardiac disorders | 0/81 | 1/80 |
| Coronary artery stenosisCardiac disorders | 1/81 | 1/80 |
| Ventricular fibrillationCardiac disorders | 0/81 | 1/80 |
| Colitis ulcerativeGastrointestinal disorders | 0/81 | 1/80 |
| Gastrointestinal angiodysplasiaGastrointestinal disorders | 0/81 | 1/80 |
| Enterococcal infectionInfections and infestations | 0/81 | 1/80 |
| Event | Placebo | Evolocumab |
|---|---|---|
| Angina pectorisCardiac disorders | 7/81 | 4/80 |
| HypertensionVascular disorders | 5/81 | 6/80 |
| MyalgiaMusculoskeletal and connective tissue disorders | 6/81 | 5/80 |
| DiarrhoeaGastrointestinal disorders | 4/81 | 3/80 |
| FatigueGeneral disorders | 2/81 | 3/80 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/81 | 3/80 |
| HypotensionVascular disorders | 1/81 | 3/80 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/81 | 0/80 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/81 | 2/80 |
| BradycardiaCardiac disorders | 0/81 | 2/80 |
| Age, Continuous(years) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 60.4 ± 9.4 | 61.1 ± 10.0 | 60.8 ± 9.6 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Female | 26 | 20 | 46 |
| Male | 56 | 62 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 81 | 78 | 159 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| White | 80 | 79 | 159 |
| Other, Not Specified | 1 | 2 | 3 |
| Stratification Factor: Statin Use at Screening(Participants) | Placebo | Evolocumab | Total |
|---|---|---|---|
| > 4 weeks of statin use | 20 | 19 | 39 |
| ≤ 4 weeks of statin use | 62 | 63 | 125 |
| Minimum Fibrous Cap Thickness (FCT)(µm) | Placebo | Evolocumab | Total |
|---|---|---|---|
| Mean | 54.6 ± 15.1 | 56.6 ± 17.8 | 55.6 ± 16.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Nov 2018 to primary completion in Dec 2020, 24 months.
Results were first posted in Nov 2021, 11 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 24 months is below that.
Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab